Full text is available at the source.
Glucagon‐like peptide‐1 receptor agonists: a narrative review of clinical pharmacology and implications for peri‐operative practice
Glucagon-like peptide-1 receptor agonists: clinical uses and considerations for surgery
AI simplified
Abstract
Evidence is limited to 10 studies assessing the risk of delayed gastric emptying and pulmonary aspiration in patients using glucagon-like peptide-1 receptor agonists.
- Patients using glucagon-like peptide-1 receptor agonists may experience delayed gastric emptying during the peri-operative period.
- Increased risk of pulmonary aspiration is a concern for individuals undergoing elective surgery while on these medications.
- Insufficient evidence exists to recommend a definitive cessation period for glucagon-like peptide-1 receptor agonists before surgery.
- Individualized, evidence-based approaches are suggested for managing patients with type 2 diabetes mellitus regarding surgical procedures.
- For weight management, glucagon-like peptide-1 receptor agonists should be withheld for at least three half-lives prior to elective surgery.
AI simplified